search
Back to results

Phenotyping of Adult Crohn's Focusing on Sarcopenia (PACS)

Primary Purpose

Inflammatory Bowel Diseases, Sarcopenia, Digestive System Disease

Status
Active
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Intrinsically labelled protein
Sponsored by
University of Nottingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Inflammatory Bowel Diseases focused on measuring Labelled protein, protein, muscle protein synthesis, muscle mass, sarcopenia, Inflammatory bowel disease, Crohn's disease, nutrition, DEXA, 13C/2H-labelled amino acids

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria for Healthy group

  1. Aged 18 years or older
  2. BMI <30 kg/m2/
  3. No previous known bowel disease
  4. Be able to provide written informed consent & participate fully in all aspects of the study.

Inclusion Criteria for Crohn's group:

  1. Aged 18 years or older.
  2. BMI <30 kg/m2
  3. Documented diagnosis of CD previously confirmed by endoscopy and histology at least 2 years prior to enrolment.
  4. Active CD defined as HBI >4 and CRP >5g/l or FCP >250ug/g or as deemed through endoscopy or cross sectional imaging.
  5. Previous biologic or immunosuppressant exposure
  6. Previous CD-related intestinal surgery
  7. Able to participate fully in all aspects of the study
  8. Written informed consent obtained and documented

Exclusion Criteria for Healthy group

  1. Aged 18 years or older
  2. BMI <30 kg/m2/
  3. No previous known bowel disease
  4. Be able to provide written informed consent & participate fully in all aspects of the study.

Exclusion Criteria for Crohn's group

  1. A current diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, or diverticular disease-associated colitis
  2. A diagnosis of short-bowel syndrome
  3. Use of systemic corticosteroids for CD (2 continuous weeks or more) within 3 months prior to enrolment, or use of any medications for HVs and CD, in the opinion of the investigator, may interfere with the subject's ability to participate fully in the study.
  4. Serious underlying disease other than CD that, in the opinion of the investigator, may interfere with the subject's ability to participate fully in the study.
  5. History of active alcohol or drug abuse that, in the opinion of the investigator, may interfere with the subject's ability to comply with the study procedures.
  6. Pregnancy or breastfeeding.
  7. Contraindications for DEXAscanning e.g. x-ray within last 7 days.
  8. Allergy to milk, , or casein

Sites / Locations

  • University of Nottingham

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Healthy group (Control group )

Crohn's group or patients group

Arm Description

This group will include healthy participants matching Crohn's group

This group will include patients with Crohn's disease.

Outcomes

Primary Outcome Measures

Postprandial muscle protein synthesis.
Postprandial muscle bound [ring-D5]-Phenylalanine, [5,5,5-D3]-Leucine as measured through mass spectrometry

Secondary Outcome Measures

Appearance/ digestibility of plasma Amino Acid in blood.
Postprandial plasma [ring-D5]-Phenylalanine, [5,5,5-D3]-Leucine as measured through mass spectrometry
Muscle mRNA expression of anabolic and catabolic
The mRNA expression of transcripts involved anabolic and catabolic signalling pathways as measured through RT-qPCR (Applied Biosystems).
Muscle protein expression of anabolic and catabolic pathway.
Muscle protein expression of anabolic and catabolic pathway signalling proteins
Serum Cytokines levels of IL-1
As measured using ELISAs
Serum Cytokines levels of IL-6
As measured using ELISAs
Serum Cytokines levels of IL-10
As measured using ELISAs
Serum Cytokines levels of CRP
As measured using ELISAs (IBDQ)
Serum Cytokines levels of TNF
Daily energy intake and dietary macronutrient composition
Appendicular Lean Mass (ALM) to Height Ratio (Kg/Height2) through DEXA scan
- It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scan will be a whole-body scan for total body composition measurement including ALM to height. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software.
Appendicular skeletal muscle index (ASMI; kg/m2) through DEXA scan.
It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scan will be a whole-body scan for total body composition measurement including ASMI. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software
Skeletal muscle index (SMI; kg/m2) through DEXA scan.
It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scan will be a whole-body scan for total body composition measurement including SMI. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software.
Skeletal Muscle Mass Percentage (SMM; %) through DEXA scan.
It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software.
Total Body Fat Percentage (BF; %) through DEXA scan.
It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software.
Fat Mass Index (FMI; kg/m2) through DEXA scan.
It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software.
Resting Metabolic Rate (RMR) through DEXA scan.
It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software.
Muscle Strength through Handgrip
Handgrip Dynamometers are instruments for measuring the maximum isometric strength of the hand and forearm muscles
Muscle Strength through Cybex Dynamometer
A CYBEX Isokinetic Test is used to measure the maximum strength of a joint throughout its available range-of-motion (ROM).
Daily physical activity
Physical activity as measured with IPAQ
Quality of life for Crohn's disease patients
measured through the Short Quality of Life Questionnaire for Inflammatory Bowel Disease
Dietary intake of one day before the experiment day.
As analysed by using intake24 website; https://intake24.co.uk/info/output . The participant will be received email included the link to fill it by what they intake on this day.

Full Information

First Posted
July 26, 2022
Last Updated
December 5, 2022
Sponsor
University of Nottingham
search

1. Study Identification

Unique Protocol Identification Number
NCT05572203
Brief Title
Phenotyping of Adult Crohn's Focusing on Sarcopenia
Acronym
PACS
Official Title
Deep Nutritional Phenotyping of Adult Crohn's Disease Patients: a Focus on Protein Intake and Sarcopenia
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 14, 2022 (Actual)
Primary Completion Date
June 1, 2023 (Anticipated)
Study Completion Date
December 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Nottingham

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Inflammatory bowel disease (IBD) includes two idiopathic chronic relapsing and remitting inflammatory conditions affecting the gastrointestinal (GI) tract: Crohn's disease (CD) and ulcerative colitis (UC)Malnutrition and significant alteration of body composition are common in inflammatory bowel disease patients, whereby the prevalence of malnutrition may be up to 82.8% in CD patients with active disease, and up to 38.9% in CD patients in remission. Many CD patients have low muscle mass and function (sarcopenia) with drivers of such pathophysiology unknown. 41.6% of CD patients with sarcopenia require surgery, with the surgical trauma and resulting inactivity leading to further muscle mass loss such that the chronic inflammatory insult associated with refractory disease may be linked to advanced muscle mass depletion. The majority of adult CD patients have low muscle mass even in clinical remission indicating the poorly reversible nature of this phenomenon. Chronic disease burden may therefore be important in the accentuation of muscle loss. Muscle mass is maintained through the daily balance of MPS and muscle protein breakdown (MPB), with the essential amino acid (EAA) components of a meal and muscle contraction being the primary stimulators of MPS. Patients with active CD show a significant decrease in the expression of proteins in hypertrophic signalling pathways (Akt, P70S6K1) with no change in the expression of atrophic signalling (MAFbx, MuRF1). Also, adult CD patients with established disease consume less protein compared to matched healthy volunteers (HV). Furthermore, the intestinal motility, measured using cine-MRI, is reduced in active CD, possibly further decreasing intestinal digestion and absorption of dietary peptides. In general, the malabsorption is a major contributing factor to malnourishment in CD. It has been shown that in male paediatric patients with long-term CD, muscle metabolism is perturbed by a negative branched-chain amino acid balance in the forearm, with this variable linked to lower appendicular muscle mass, higher muscle fatigue and reduced protein intake, CD may have a significant effect on protein digestion and absorption, and blunt the MPS response to feeding, leading to a chronic muscle mass reduction that may persist even when in remission. The EAA components of a protein meal are crucial for the stimulation of muscle protein synthesis (MPS), and all the EAA/leucine play a key role in driving MPS. Low serum levels EAA/leucine have been reported in CD but their role in the aetiology of sarcopenia in CD is unknown. Further, how CD affects the protein digestion/absorption and how this contributes to low EAA/leucine unclear. Recent advances in stable isotope tracer techniques using a dual tracer methodology now enable a more accurate determination of protein digestibility. By following the appearance of intrinsically labelled AAs into the blood upon digestion of the intrinsically labelled protein, alongside the appearance of label-free AAs, protein digestibility can be accurately determined. Further, by collecting a muscle biopsy postprandially, the direct incorporation of AA from the digested protein into the muscle can be determined- providing a gold standard method for investigating anabolic resistance. Project aim is to use an intrinsically labelled casein to investigate protein digestion, absorption and MPS responses in CD patients. To achieve this, investigators will investigate protein digestion, absorption and muscle protein synthesis responses in Crohn's disease patients and healthy volunteers by utilising intrinsically labelled protein.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Inflammatory Bowel Diseases, Sarcopenia, Digestive System Disease, Nutrition, Healthy, Protein Malabsorption, Crohn Disease
Keywords
Labelled protein, protein, muscle protein synthesis, muscle mass, sarcopenia, Inflammatory bowel disease, Crohn's disease, nutrition, DEXA, 13C/2H-labelled amino acids

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
35 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Healthy group (Control group )
Arm Type
Active Comparator
Arm Description
This group will include healthy participants matching Crohn's group
Arm Title
Crohn's group or patients group
Arm Type
Experimental
Arm Description
This group will include patients with Crohn's disease.
Intervention Type
Dietary Supplement
Intervention Name(s)
Intrinsically labelled protein
Other Intervention Name(s)
Intrinsically labelled Casein
Intervention Description
It is a protein drink that includes Intrinsically labelled Casein ( from Arla Foods), 13C/2H-labelled Spirulina (from CK Isotopes), and 13C/2H-labelled amino acids (from CK Isotopes)
Primary Outcome Measure Information:
Title
Postprandial muscle protein synthesis.
Description
Postprandial muscle bound [ring-D5]-Phenylalanine, [5,5,5-D3]-Leucine as measured through mass spectrometry
Time Frame
Change from baseline 4 hours (Two time points)
Secondary Outcome Measure Information:
Title
Appearance/ digestibility of plasma Amino Acid in blood.
Description
Postprandial plasma [ring-D5]-Phenylalanine, [5,5,5-D3]-Leucine as measured through mass spectrometry
Time Frame
blood samples will be taken at regular intervals up to 240 minutes (max 120ml total blood draw post protein drink). 12-time points
Title
Muscle mRNA expression of anabolic and catabolic
Description
The mRNA expression of transcripts involved anabolic and catabolic signalling pathways as measured through RT-qPCR (Applied Biosystems).
Time Frame
Change from baseline at 4 hours (Two time points).
Title
Muscle protein expression of anabolic and catabolic pathway.
Description
Muscle protein expression of anabolic and catabolic pathway signalling proteins
Time Frame
Change from baseline at 4 hours (Two time points).
Title
Serum Cytokines levels of IL-1
Description
As measured using ELISAs
Time Frame
Only at baseline.
Title
Serum Cytokines levels of IL-6
Description
As measured using ELISAs
Time Frame
Only at baseline.
Title
Serum Cytokines levels of IL-10
Description
As measured using ELISAs
Time Frame
Only at baseline.
Title
Serum Cytokines levels of CRP
Description
As measured using ELISAs (IBDQ)
Time Frame
Only at baseline.
Title
Serum Cytokines levels of TNF
Description
Daily energy intake and dietary macronutrient composition
Time Frame
Only at baseline.
Title
Appendicular Lean Mass (ALM) to Height Ratio (Kg/Height2) through DEXA scan
Description
- It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scan will be a whole-body scan for total body composition measurement including ALM to height. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software.
Time Frame
Only at baseline
Title
Appendicular skeletal muscle index (ASMI; kg/m2) through DEXA scan.
Description
It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scan will be a whole-body scan for total body composition measurement including ASMI. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software
Time Frame
Only at baseline
Title
Skeletal muscle index (SMI; kg/m2) through DEXA scan.
Description
It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scan will be a whole-body scan for total body composition measurement including SMI. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software.
Time Frame
Only at baseline
Title
Skeletal Muscle Mass Percentage (SMM; %) through DEXA scan.
Description
It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software.
Time Frame
Only at baseline
Title
Total Body Fat Percentage (BF; %) through DEXA scan.
Description
It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software.
Time Frame
Only at baseline
Title
Fat Mass Index (FMI; kg/m2) through DEXA scan.
Description
It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software.
Time Frame
Only at baseline
Title
Resting Metabolic Rate (RMR) through DEXA scan.
Description
It will be assessed via DEXA scan using a GE Lunar Prodigy DEXA scanner housed in the University of Nottingham's David Greenfield unit. The scans will be analysed using the scanners inbuilt Corescan software. Regional measurements will be taken post scan using custom analysis functions within the Corescan software.
Time Frame
Only at baseline
Title
Muscle Strength through Handgrip
Description
Handgrip Dynamometers are instruments for measuring the maximum isometric strength of the hand and forearm muscles
Time Frame
Only at baseline
Title
Muscle Strength through Cybex Dynamometer
Description
A CYBEX Isokinetic Test is used to measure the maximum strength of a joint throughout its available range-of-motion (ROM).
Time Frame
Only at baseline
Title
Daily physical activity
Description
Physical activity as measured with IPAQ
Time Frame
Only at baseline
Title
Quality of life for Crohn's disease patients
Description
measured through the Short Quality of Life Questionnaire for Inflammatory Bowel Disease
Time Frame
Only at baseline
Title
Dietary intake of one day before the experiment day.
Description
As analysed by using intake24 website; https://intake24.co.uk/info/output . The participant will be received email included the link to fill it by what they intake on this day.
Time Frame
Only at baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria for Healthy group Aged 18 years or older BMI <30 kg/m2/ No previous known bowel disease Be able to provide written informed consent & participate fully in all aspects of the study. Inclusion Criteria for Crohn's group: Aged 18 years or older. BMI <30 kg/m2 Documented diagnosis of CD previously confirmed by endoscopy and histology at least 2 years prior to enrolment. Active CD defined as HBI >4 and CRP >5g/l or FCP >250ug/g or as deemed through endoscopy or cross sectional imaging. Previous biologic or immunosuppressant exposure Previous CD-related intestinal surgery Able to participate fully in all aspects of the study Written informed consent obtained and documented Exclusion Criteria for Healthy group Aged 18 years or older BMI <30 kg/m2/ No previous known bowel disease Be able to provide written informed consent & participate fully in all aspects of the study. Exclusion Criteria for Crohn's group A current diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, or diverticular disease-associated colitis A diagnosis of short-bowel syndrome Use of systemic corticosteroids for CD (2 continuous weeks or more) within 3 months prior to enrolment, or use of any medications for HVs and CD, in the opinion of the investigator, may interfere with the subject's ability to participate fully in the study. Serious underlying disease other than CD that, in the opinion of the investigator, may interfere with the subject's ability to participate fully in the study. History of active alcohol or drug abuse that, in the opinion of the investigator, may interfere with the subject's ability to comply with the study procedures. Pregnancy or breastfeeding. Contraindications for DEXAscanning e.g. x-ray within last 7 days. Allergy to milk, , or casein
Facility Information:
Facility Name
University of Nottingham
City
Nottingham
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
19112190
Citation
Benjamin J, Makharia GK, Kalaivani M, Joshi YK. Nutritional status of patients with Crohn's disease. Indian J Gastroenterol. 2008 Sep-Oct;27(5):195-200.
Results Reference
background
PubMed Identifier
26010896
Citation
Brook MS, Wilkinson DJ, Phillips BE, Perez-Schindler J, Philp A, Smith K, Atherton PJ. Skeletal muscle homeostasis and plasticity in youth and ageing: impact of nutrition and exercise. Acta Physiol (Oxf). 2016 Jan;216(1):15-41. doi: 10.1111/apha.12532. Epub 2015 Jun 21.
Results Reference
background
PubMed Identifier
25827594
Citation
Bukhari SS, Phillips BE, Wilkinson DJ, Limb MC, Rankin D, Mitchell WK, Kobayashi H, Greenhaff PL, Smith K, Atherton PJ. Intake of low-dose leucine-rich essential amino acids stimulates muscle anabolism equivalently to bolus whey protein in older women at rest and after exercise. Am J Physiol Endocrinol Metab. 2015 Jun 15;308(12):E1056-65. doi: 10.1152/ajpendo.00481.2014. Epub 2015 Mar 31.
Results Reference
background
PubMed Identifier
30083065
Citation
Chiba T, Suzuki K, Matsumoto T. Plasma-Free Amino Acid Profiles in Crohn's Disease: Relationship With the Crohn Disease Activity Index. Clin Med Insights Gastroenterol. 2018 Jul 30;11:1179552218791173. doi: 10.1177/1179552218791173. eCollection 2018.
Results Reference
background
PubMed Identifier
15596483
Citation
Cuthbertson D, Smith K, Babraj J, Leese G, Waddell T, Atherton P, Wackerhage H, Taylor PM, Rennie MJ. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB J. 2005 Mar;19(3):422-4. doi: 10.1096/fj.04-2640fje. Epub 2004 Dec 13.
Results Reference
background
PubMed Identifier
24155732
Citation
Dalton M, Blundell J, Finlayson GS. Examination of food reward and energy intake under laboratory and free-living conditions in a trait binge eating subtype of obesity. Front Psychol. 2013 Oct 21;4:757. doi: 10.3389/fpsyg.2013.00757. eCollection 2013.
Results Reference
background
PubMed Identifier
31178247
Citation
Davies A, Nixon A, Muhammed R, Tsintzas K, Kirkham S, Stephens FB, Moran GW. Reduced skeletal muscle protein balance in paediatric Crohn's disease. Clin Nutr. 2020 Apr;39(4):1250-1257. doi: 10.1016/j.clnu.2019.05.017. Epub 2019 May 25.
Results Reference
background
PubMed Identifier
29771297
Citation
Devi S, Varkey A, Sheshshayee MS, Preston T, Kurpad AV. Measurement of protein digestibility in humans by a dual-tracer method. Am J Clin Nutr. 2018 Jun 1;107(6):984-991. doi: 10.1093/ajcn/nqy062.
Results Reference
background
PubMed Identifier
19496185
Citation
Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol. 2009 Jun 7;15(21):2570-8. doi: 10.3748/wjg.15.2570.
Results Reference
background
PubMed Identifier
30230099
Citation
Khalaf A, Nowak A, Menys A, Marciani L, Taylor SA, Spiller RC, Gowland PA, Moran GW, Hoad CL. Cine MRI assessment of motility in the unprepared small bowel in the fasting and fed state: Beyond the breath-hold. Neurogastroenterol Motil. 2019 Jan;31(1):e13466. doi: 10.1111/nmo.13466. Epub 2018 Sep 19.
Results Reference
background
PubMed Identifier
31391776
Citation
Li S, Ney M, Eslamparast T, Vandermeer B, Ismond KP, Kroeker K, Halloran B, Raman M, Tandon P. Systematic review of nutrition screening and assessment in inflammatory bowel disease. World J Gastroenterol. 2019 Jul 28;25(28):3823-3837. doi: 10.3748/wjg.v25.i28.3823.
Results Reference
background
PubMed Identifier
18689367
Citation
Moshfegh AJ, Rhodes DG, Baer DJ, Murayi T, Clemens JC, Rumpler WV, Paul DR, Sebastian RS, Kuczynski KJ, Ingwersen LA, Staples RC, Cleveland LE. The US Department of Agriculture Automated Multiple-Pass Method reduces bias in the collection of energy intakes. Am J Clin Nutr. 2008 Aug;88(2):324-32. doi: 10.1093/ajcn/88.2.324.
Results Reference
background
PubMed Identifier
31529051
Citation
Moughan PJ, Wolfe RR. Determination of Dietary Amino Acid Digestibility in Humans. J Nutr. 2019 Dec 1;149(12):2101-2109. doi: 10.1093/jn/nxz211.
Results Reference
background
PubMed Identifier
24751956
Citation
Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014 May;14(5):329-42. doi: 10.1038/nri3661. Epub 2014 Apr 22.
Results Reference
background
PubMed Identifier
31554166
Citation
Pizzoferrato M, de Sire R, Ingravalle F, Mentella MC, Petito V, Martone AM, Landi F, Miggiano GAD, Mele MC, Lopetuso LR, Schiavoni E, Napolitano D, Turchini L, Poscia A, Nicolotti N, Papa A, Armuzzi A, Scaldaferri F, Gasbarrini A. Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center. Nutrients. 2019 Sep 24;11(10):2281. doi: 10.3390/nu11102281.
Results Reference
background
PubMed Identifier
18631418
Citation
Rocha R, Santana GO, Almeida N, Lyra AC. Analysis of fat and muscle mass in patients with inflammatory bowel disease during remission and active phase. Br J Nutr. 2009 Mar;101(5):676-9. doi: 10.1017/S0007114508032224.
Results Reference
background
PubMed Identifier
29889230
Citation
Ryan E, McNicholas D, Creavin B, Kelly ME, Walsh T, Beddy D. Sarcopenia and Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis. 2019 Jan 1;25(1):67-73. doi: 10.1093/ibd/izy212.
Results Reference
background
PubMed Identifier
16151544
Citation
Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Pena AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A. doi: 10.1155/2005/269076.
Results Reference
background
PubMed Identifier
24332699
Citation
van Langenberg DR, Della Gatta P, Hill B, Zacharewicz E, Gibson PR, Russell AP. Delving into disability in Crohn's disease: dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease. J Crohns Colitis. 2014 Jul;8(7):626-34. doi: 10.1016/j.crohns.2013.11.024. Epub 2013 Dec 13.
Results Reference
background
PubMed Identifier
29617753
Citation
Wardle RA, Thapaliya G, Nowak A, Radford S, Dalton M, Finlayson G, Moran GW. An Examination of Appetite and Disordered Eating in Active Crohn's Disease. J Crohns Colitis. 2018 Jun 28;12(7):819-825. doi: 10.1093/ecco-jcc/jjy041.
Results Reference
background
PubMed Identifier
28852372
Citation
Wolfe RR. Branched-chain amino acids and muscle protein synthesis in humans: myth or reality? J Int Soc Sports Nutr. 2017 Aug 22;14:30. doi: 10.1186/s12970-017-0184-9. eCollection 2017.
Results Reference
background

Learn more about this trial

Phenotyping of Adult Crohn's Focusing on Sarcopenia

We'll reach out to this number within 24 hrs